HER2 amplification is an emerging biomarker in colorectal cancer that confers to combination anti-HER2 treatment and predicts resistance to EGFR blockage, although the frequency of HER2 amplification is relatively low. The gene discussed is ERBB2; the disease is colorectal cancer.